Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies

SUMMARY: BACKGROUND: The mixed μ‐ and κ‐opioid receptor agonist and δ‐opioid receptor antagonist, eluxadoline, is licensed in the USA for the treatment of irritable bowel syndrome with diarrhoea (IBS‐D), based on the results of two large Phase 3 clinical trials. AIM: To understand the time course of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chey, W. D., Dove, L. S., Andrae, D. A., Covington, P. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Eluxadoline for Irritable Bowel Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413805/
https://www.ncbi.nlm.nih.gov/pubmed/28326568
http://dx.doi.org/10.1111/apt.14031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413805/
https://www.ncbi.nlm.nih.gov/pubmed/28326568
http://dx.doi.org/10.1111/apt.14031

Ejemplares similares